Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K5+ Elvatan versus topical tranexamic acid for melasma
IRCT20260514069400N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tranexamic acid in melasma (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Change in Melasma Area and Severity Index score and Change in darkness of melasma lesions. Started Jun 2026; status: completed.
02
Drugs
tranexamic acid
03
Conditions
melasma
Beyond the preview
Go deeper on IRCT20260514069400N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260514069400N1.